Do You Need a License to Sell Peptides in South Dakota?

There is no single permit called a "peptide license" that a state hands out. What actually applies to your business breaks into three separate questions: whether you are properly registered and authorized to do business and collect sales tax at all, whether what you are distributing falls under drug or pharmacy distribution frameworks, and whether you are operating inside the research-use-only lane, where compounds move business-to-business for laboratory research and are never sold, labeled, or represented for human use. Those three questions have three different answers, three different authorities, and three different sets of consequences if you guess. This article walks through how to sort them out — it is informational only and is not legal advice. Your attorney and the relevant state boards are the only sources that can give you a binding answer for your specific setup.

Three questions hiding inside one

Most operators searching this phrase are really asking one of three very different things, and the confusion is what gets people into trouble.

The first question is ordinary commercial: is your entity formed, registered, and authorized to sell anything in the state where you operate? That is a business registration and tax question, and it has nothing to do with peptides specifically. It applies identically whether you are stocking research compounds, skincare, or office chairs. Your accountant and your secretary of state's business filing office handle this layer, and it is usually the least ambiguous part of the whole picture.

The second question is the one people mean but rarely phrase correctly: does the specific thing I am selling trigger drug distribution, wholesale distributor, or pharmacy licensure requirements? This is where it stops being a general business question and becomes a regulatory classification question. Classification depends on what the substance is, how it is labeled, what claims accompany it, who it is sold to, and what it is represented as being for. Change any one of those variables and the answer can change with it. No supplier — including Real Peptides — can make that determination on your behalf, and any supplier that tells you flatly that no license is required anywhere is telling you something they cannot know.

The third question is about lane discipline: are you actually staying inside research-use-only distribution, or has your marketing, packaging, or customer conversation quietly moved you somewhere else? This is the question that trips up otherwise careful businesses, because it is not answered by a filing. It is answered by the totality of how you present and sell.

What the research-use-only lane commits you to

Research-use-only is not a disclaimer you paste at the bottom of a product page. It is an operating posture, and it constrains what you can say, how you can label, who you can sell to, and what your website is allowed to imply.

In practice, staying in the lane means the compounds are sold for laboratory and research applications only. It means no dosing information, no administration guidance, no protocols, no before-and-after imagery, and no framing that suggests a compound addresses a condition in a person. It means not pairing compounds with supplies in a way that assembles something resembling a use kit. It means your product copy describes what a compound is and what the published research has examined — hedged honestly, because research suggests is not the same as research proves — rather than what it will do for someone.

It also means your downstream customer matters. Selling to research organizations and businesses is a different posture than selling to walk-in consumers, and the further you drift toward the latter, the harder it becomes to defend the classification you have claimed. Real Peptides supplies research-use-only compounds to businesses under its Wholesale Partner Program; how a partner structures its own downstream sales, and what that structure requires of it, is a question for that partner's counsel.

One more point worth stating plainly: none of the compounds in a research catalog are FDA-approved drugs, and none should ever be described as approved, proven, or cleared. Real Peptides does not supply semaglutide, tirzepatide, retatrutide, or melanotan through its wholesale program, and any conversation that begins by asking for those is a conversation about a different regulatory category entirely.

The questions to put to your attorney and the relevant board

Rather than hunting for a rule that says yes or no, bring a structured list to the people who can actually answer. The table below is the shape of that conversation.

Generally speaking, in most states the layers stack rather than substitute: a business registration does not answer a distribution question, and a distribution answer does not resolve a scope-of-practice question. Ask all of them. And ask them before you place a first order, not after inventory is sitting on a shelf. Check with your state board and your attorney on every specific — this page describes the shape of the inquiry, not its outcome.

Where your supplier's paperwork becomes your paperwork

Here is the part most buyers underestimate. Whatever your own compliance posture, your supplier's documentation becomes part of your record the moment you take delivery. If a regulator, a payment processor, an insurer, or simply a serious customer asks what is in a vial and how you know, your answer is only as strong as the paperwork behind it.

That is why certificate of analysis practice is a compliance issue and not a marketing nicety. A COA should be tied to the specific batch you received, not to a representative sample from an unrelated lot. It should show identity and purity by a stated analytical method, and it should be verifiable by you — meaning you can open it, read it, and match it to what is in your hands without paying a fee or filing a request.

Several common industry practices should give a buyer pause. COAs sold as an add-on rather than published turn a basic quality record into a revenue line. Testing described as "third-party verified" with no lab named and no document produced is unverifiable by definition. Pricing that exists only behind a phone call makes cost modeling impossible and tends to correlate with inconsistent terms between accounts. None of this means a given supplier is doing anything wrong; it means you cannot tell, and in a category where documentation is the whole defense, not being able to tell is the problem.

Before committing volume, get concrete answers on: batch-level testing and what panels are run, whether COAs are published openly, where fulfillment originates and what the realistic timeline is, how out-of-spec material is handled, how lot traceability works, and whether pricing tiers and minimums are stated in writing.

What Real Peptides does differently

Real Peptides publishes what most of this category keeps behind a login. Purity is specified at 99%+ by HPLC. Batches go through a multi-panel testing protocol covering identity, purity, and contaminant screening, and the resulting certificates of analysis are publicly verifiable — a prospective partner can read the lab results before speaking to anyone, rather than taking a claim on faith. That is a deliberate inversion of the norm in this market, where documentation is often the thing you have to ask for twice.

Fulfillment runs from within the United States, with orders shipping in five to seven days. The catalog is broad enough to build a coherent research offering rather than a handful of one-off SKUs — partners stocking their shelves typically start from the most-requested research compounds and expand into specialized categories as their customer base defines itself.

Qualification runs through a three-step wholesale application: submit the application with your business details, get reviewed for fit, and receive tiered pricing and account terms. Pricing tiers and minimums are stated to applicants rather than negotiated ad hoc, which matters if you intend to model margin against volume with any accuracy. Margins themselves vary widely with volume, category, and how a partner positions its own offering — anyone quoting you a specific markup range sight-unseen is guessing.

What Real Peptides does not do is make a licensing determination for you. No supplier can. A supplier can tell you exactly what it is shipping, what testing backs it, and where the documentation lives. Everything downstream of that — your entity, your registrations, your customers, your claims — is yours and your counsel's.

Getting from question to qualified account

The sequence that works is unglamorous. Settle your entity and registration questions first. Take the classification and scope questions to a regulatory attorney and, where relevant, to the applicable state board, and get the answer in writing rather than in a phone call you half-remember. Decide deliberately which lane you are operating in and build your labeling, your website copy, and your sales conversations to match it. Only then evaluate suppliers — and evaluate them on documentation you can verify yourself, not on claims you would have to trust.

If that groundwork is done and you are ready to source, the Wholesale Partner Program application is the next step: it collects your business details, confirms fit, and returns tiered pricing so you can plan against real numbers instead of estimates.

For more on how the program is structured and how tiers work, see the wholesale peptides program overview, read the broader breakdown of do you need a license to sell peptides, or apply for a wholesale account directly.